{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:57:50Z","timestamp":1776725870135,"version":"3.51.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare autoimmune disease characterized by skeletal muscle weakness. As limited real-world data are available in Japan, we aimed to describe the humanistic burden of disease (primary aim), mainly with regards to health-related quality of life (HRQoL), and treatment patterns (secondary aim) in patients with generalized MG (gMG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were drawn from the Adelphi Real World MG Disease Specific Programme\u2122, a cross-sectional survey of neurologists and their patients in Japan from August 2023 and January 2024. Analyses were descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 40 neurologists reported data for 128 patients, where 29 patients had self-reported data. Mean (standard deviation) patient age was 57.9 (16.0) years and 53.9% were female. At data collection, 98.4% of patients were receiving maintenance therapy (including novel treatments). Nonsteroidal immunosuppressant therapies were used at first-line of therapy in 54.5% of cases (\n                      <jats:italic>n<\/jats:italic>\n                      = 67\/123). Oral systemic steroids were most used [78.0% of patients at first-line (\n                      <jats:italic>n<\/jats:italic>\n                      = 96\/123), 77.9% at second-line (\n                      <jats:italic>n<\/jats:italic>\n                      = 53\/68), and 75.0% at third-line (\n                      <jats:italic>n<\/jats:italic>\n                      = 15\/20)]. The median (IQR) duration from symptom onset to diagnosis was 2.0 (0.9\u20134.3) months. Of 28 patients with EQ-5D-5L data, 46.4% reported difficulties with usual activities, 42.9% with mobility, 21.4% with self-care, 53.6% with pain\/discomfort, and 39.3% with anxiety\/depression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most patients in this Japanese cohort with gMG received maintenance therapy and the time from symptom onset to diagnosis was relatively short. However, impaired HRQoL remained.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1673297","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:04:12Z","timestamp":1765555452000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Humanistic burden and medical care patterns of real-world patients with myasthenia gravis in Japan"],"prefix":"10.3389","volume":"16","author":[{"given":"Mami","family":"Kasahara-Kiritani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Saga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keira","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DaeYoung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara","family":"Ringland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva Lauretta","family":"Birija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Conyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Hatchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e068104","DOI":"10.1136\/bmjopen-2022-068104","article-title":"Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)","volume":"13","author":"Berrih-Aknin","year":"2023","journal-title":"BMJ Open."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","article-title":"Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG","volume":"13","author":"Dewilde","year":"2023","journal-title":"BMJ Open."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40120-024-00617-6","article-title":"Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients' perspectives in Japan","volume":"13","author":"Kawaguchi","year":"2024","journal-title":"Neurol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e013278","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0274161","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fneur.2025.1625457","article-title":"Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the medical data vision database in Japan","author":"Teranishi","year":"2025","journal-title":"Front Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1756285617749134","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan MG registry: chronological surveys over 10 years","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specifics programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open."},{"key":"B16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes."},{"key":"B17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"70","author":"Jaretzki A","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve."},{"key":"B22","unstructured":"EQ-5D-5L User Guide 2019\n          \n          2019"},{"key":"B23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jval.2016.03.1834","article-title":"Comparison of value set based on DCE and\/or TTO data: scoring for EQ-5D-5L health states in Japan","volume":"19","author":"Shiroiwa","year":"2016","journal-title":"Value Health."},{"key":"B24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage."},{"key":"B26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/geront\/41.5.652","article-title":"The Zarit burden interview: a new short version and screening version","volume":"41","author":"B\u00e9dard","year":"2001","journal-title":"Gerontologist."},{"key":"B27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2377-12-156","article-title":"Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients' behavioral changes than physical disability: a comparative study","volume":"12","author":"Lillo","year":"2012","journal-title":"BMC Neurol."},{"key":"B28","year":"2021","journal-title":"Intelligence Reporter Version 7.5"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","article-title":"Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings","volume":"24","author":"Shiroiwa","year":"2021","journal-title":"Value Health."},{"key":"B30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve."},{"key":"B31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1016\/j.jval.2023.03.1848","article-title":"PCR70 patient and physician concordance in treatment satisfaction and symptom severity among male and female myasthenia gravis patients in the united states and five European countries","volume":"26","author":"Pesa","year":"2023","journal-title":"Value Health."},{"key":"B34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"B35","unstructured":"Code of Conduct 2024\n          \n          2024"},{"key":"B36","unstructured":"Ethical Guidelines for Life Science and Medical Research Involving Human Subjects (Main Text)\n          \n          2023"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 Update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1673297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:04:13Z","timestamp":1765555453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1673297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":37,"alternative-id":["10.3389\/fneur.2025.1673297"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1673297","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"article-number":"1673297"}}